NOV Antibody

說明書

中文名稱：

NOV兔多克隆抗體
貨號：

CSB-PA987170
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using CSB-PA987170(NOV Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA987170(NOV Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)

Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: CSB-PA987170(NOV Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

P48745
基因名：

NOV
別名：

CCN family member 3 antibody; CCN3 antibody; IBP-9 antibody; IGF-binding protein 9 antibody; IGFBP-9 antibody; IGFBP9 antibody; Insulin-like growth factor-binding protein 9 antibody; Nephroblastoma overexpressed antibody; Nephroblastoma overexpressed gene protein homolog antibody; Nephroblastoma-overexpressed gene protein homolog antibody; NOV antibody; NOV_HUMAN antibody; NovH antibody; Protein NOV homolog antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human NOV
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
WB	1:500-1:2000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival. Acts by binding to integrins or membrane receptors such as NOTCH1. Essential regulator of hematopoietic stem and progenitor cell function. Inhibits myogenic differentiation through the activation of Notch-signaling pathway. Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling. Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival. Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts. Involved in bone regeneration as a negative regulator. Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification. Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion. Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway. Contributes to the control and coordination of inflammatory processes in atherosclerosis. Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement.
基因功能參考文獻：
1. A significant reduction of CCN3 expression was observed in lesioned skin compared to non-lesioned skin in vitiligo patients. PMID: 29998862
2. This is the first evidence of downregulation of TGFbeta1-mediated activation of a Smad1/5/8 signalling pathway by CCN3 in human podocytes and in any cell type. PMID: 29506624
3. NOV is a novel biomarker of the presence and severity of OSA and a potential marker of future cardiovascular and metabolic disease in OSA patients. PMID: 28862983
4. down-regulation of Lamin B1 and up-regulation of Nephroblastoma overexpressed (NOV) are at least partially responsible for the inhibitory effect of Huaier on the proliferative and invasive capacity of SKHEP-1 cells PMID: 27503760
5. NOV is down-regulated in CRC tumours which is associated with disease progression. PMID: 28412738
6. Taken together, our results suggest that palmitoylation by ZDHHC22 at C241 in the CCN3 TSP1 domain may be required for the secretion of CCN3. Aberrant palmitoylation induces intracellular accumulation of CCN3, inhibiting neuronal axon growth. PMID: 29287726
7. CCN3 (Nov) and CCN5 (WISP2) are novel substrates of MMP14. PMID: 27471094
8. Reduced levels of CCN1 and CCN3, as found in early-onset preeclampsia, could contribute to a shift from invasive to proliferative extravillous trophoblasts and may explain their shallow invasion properties in this disease. PMID: 26744771
9. our findings establish CCN3 as a pivotal regulator of androgen receptor (AR) signaling and prostate cancer progression and suggest a functional intersection between EZH2 and AR signaling in castration-resistant prostate cancer PMID: 27815387
10. The present study aimed to examine the clinical relevance of NOV along with CYR61 and CTGF in gastric cancer by analysing their transcript levels...the expression of NOV and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV promoted proliferation and invasion of gastric cancer cells PMID: 27633176
11. Studies indicate that the CYR61 CTGF NOV matricellular proteins (CCN family of proteins) comprises the members CCN1, CCN2, CCN3, CCN4, CCN5 and CCN6 and have been identified in various types of cancer. PMID: 26498181
12. NOV expression was highly increased in biopsies of patients with tubulointerstitial nephritis. PMID: 26367310
13. Results revealed that NOV regulates the tumor growth of osteosarcoma cells through activation of the MAPK signaling pathway and promotes osteosarcoma cell migration in vitro. PMID: 26238193
14. our results argue that MZF-1 regulates the CTGF and NOV genes in the hematopoietic compartment, and may be involved in their respective functions in the stroma. PMID: 25899830
15. Overexpression of CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. PMID: 24721786
16. NOV may promote carcinogenesis via promotion of EMT and association with increased mTOR activity PMID: 24719190
17. over-expression of NOV in pancreatic cancer cells promoted cell proliferation and migration, while knock down the expression of NOV impaired the tumorigenecity of pancreatic cancer cells in vitro and in vivo PMID: 24258112
18. CCN3 may play an important role in cervical carcinogenesis and therefore may have potential as a biomarker for prognosis and as a therapeutic target in cervical cancer. PMID: 24431313
19. Our findings establish a tumor-suppressive role of NOV in prostate cancer PMID: 23318417
20. in obese humans and mice plasma NOV levels positively correlated with NOV expression in adipose tissue, and support a possible contribution of NOV to obesity-related inflammation. PMID: 23785511
21. These results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic beta-cells. PMID: 23705021
22. Presence of both forms of CCN3 is accompanied by a balance of trophoblast proliferation and migration/invasion properties, which are triggered by different signalling pathways. PMID: 23220688
23. CCN3 expression is higher in highly invasive PC3 cells. PMID: 23536580
24. Data suggest that urinary CCN3/CCN2 mRNA ratio may be a useful noninvasive biomarker for evaluating patients with nondiabetic chronic kidney disease (CKD) prior to renal biopsy. PMID: 23061738
25. Melanocytes remaining in perilesional vitiligo skin did not express CCN3. PMID: 22507556
26. results indicate that CCN3 enhances the migration of prostate cancer cells by increasing ICAM-1 expression through a signal transduction pathway that involves alphavbeta3 integrin, ILK, Akt and NF-kappaB PMID: 22345292
27. Provide evidence that CCN3 enhances BMP-4 expression and bone nodule formation in osteoblasts, and that the integrin receptor, ILK, p38, JNK, and AP-1 signaling pathways may be involved. PMID: 21898398
28. CCN3 protein regulates the decrease in Jeg3 cell numbers independent of its glycosylation status PMID: 21784733
29. CCN3 enhances the migration of chondrosarcoma cells by increasing MMP-13 expression through the alphavbeta3/alphavbeta5 integrin receptor, FAK, PI3K, Akt, p65, and NF-kappaB signal transduction pathway. PMID: 21344378
30. Data show reduced CCN3 levels in aRMS cells following small interfering RNA knockdown of PAX3-FKHR. PMID: 21423212
31. CCN3 regulates the differentiation of bone resident cells to create a resorptive environment that promotes the formation of osteolytic breast cancer metastases PMID: 21514448
32. Recombinant expression, purification, and functional characterisation of connective tissue growth factor and nephroblastoma-overexpressed protein PMID: 21209863
33. NOV acts through alphavbeta5 integrin to activate ILK and Akt, which in turn activates c-Jun and AP-1, resulting in the activations of COX-2 and contributing the migration of human osteosarcoma cells. PMID: 21145881
34. Only defined binding properties between Cx43 and CCN3 leading to an upregulation of CCN3 are needed for signaling. PMID: 20336664
35. CYR61 and NOV are regulated by HIF-1alpha and TGF-beta3 in the trophoblast cell line JEG3, and their enhanced secretion could be implicated in appropriate placental invasion. PMID: 20237132
36. CCN3 counter-regulates positive signals from TGF-beta and Wnt for fibrillin fibrillogenesis and profibrotic gene expression. PMID: 20182440
37. These findings identify a new paracrine role of NOV in the development of cerebellar granule neurons. PMID: 19286457
38. CCN3 suppresses neointimal thickening through the inhibition of vascular smooth cell migration and proliferation. PMID: 20139355
39. The angiogenic gene CCN3/nov was specifically downregulated in the plexiform neurofibromas and malignant peripheral nerve sheath tumor. PMID: 20010302
40. expression of this protein appears to be associated with a higher risk of developing metastases in Ewing's sarcoma PMID: 11891184
41. association with Notch1 extracellular domain and inhibition of myoblast differentiation via Notch signaling pathway PMID: 12050162
42. NOVH concentration was significantly modified in malignant but not benign adrenocortical tumors; the concentration of NOVH was significantly decreased in patients suffering from astrocytomas or multiple sclerosis PMID: 12519873
43. in endothelial cells, CCN3 supports cell adhesion, induces directed cell migration (chemotaxis), and promotes cell survival PMID: 12695522
44. NOVH increases cell adhesion and migration of glioblastoma cells via matrix metalloprotease 3 expression and a PDGFR-alpha dependent mechanism. PMID: 14519668
45. evidence that adenylate cyclase as well as one or several protein kinases might be involved in the mechanoregulation of Cyr61, CTGF and Nov genes PMID: 15053922
46. Cx43 is able to regulate cell growth via an up-regulation of NOV transcription PMID: 15181016
47. CCN3 has a role in cutaneous wound healing in skin fibroblasts PMID: 15611078
48. expression of CCN3 in Ewing's sarcoma primary tumors may be associated with a higher risk of developing lung and/or bone metastases PMID: 15824736
49. Data indicates that NOV is associated with carcinogenesis and the progression of renal cell carcinoma, and the NOV expression level is different in papillary-type and clear cell-type RCC. PMID: 16145471
50. Results suggest that NOV (nephroblastoma overexpressed) is a specific cell fate regulator in the myogenic lineage, acting negatively on key myogenic genes thus controlling the transition from progenitor cells to myoblasts. PMID: 16600215
顯示更多

收起更多
亞細胞定位：

Secreted. Cytoplasm. Cell junction, gap junction.
蛋白家族：

CCN family
組織特異性：

Expressed in endiothelial cells (at protein level). Expressed in bone marrow, thymic cells and nephroblastoma. Increased expression in Wilms tumor of the stromal type.
數(shù)據(jù)庫鏈接：

HGNC: 7885

OMIM: 164958

KEGG: hsa:4856

STRING: 9606.ENSP00000259526

UniGene: Hs.235935

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat